This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing that we have revised the Advisory Committee Information Hotline (the hotline). The hotline provides the public with access to the most current information available on FDA advisory committee meetings. This notice supersedes all previously published announcements of FDA's Advisory Committee Information Hotline.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Michael F. Ortwerth, Director, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.End Further Info End Preamble Start Supplemental Information
The Advisory Committee Information Hotline can be accessed by dialing 1-800-741-8138 or 301-443-0572. The advisory committee meeting information and information updates can also be accessed via FDA's Advisory Committee Internet site at http://www.fda.gov/AdvisoryCommittees/default.htm.
Each advisory committee is assigned a 10-digit number. This 10-digit number will appear in each individual notice of meeting. The public can obtain information about a particular advisory committee meeting by using the committee's 10-digit number. Information on the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made. The following is a list of each advisory committee's 10-digit number to be used when accessing the hotline. The list has been updated to add the newly established advisory committee in the Center for Tobacco called the Tobacco Products Scientific Advisory Committee.
|Advisory Committee||10-Digit Access Number|
|OFFICE OF THE COMMISSIONER|
|Pediatric Advisory Committee||8732310001|
|Risk Communication Advisory Committee||8732112560|
|Science Board to the FDA||3014512603|
|CENTER FOR BIOLOGICS EVALUATION AND RESEARCH|
|Allergenic Products Advisory Committee||3014512388|
|Blood Products Advisory Committee||3014519516|
|Cellular, Tissue & Gene Therapies Advisory Committee||3014512389|
|Transmissible Spongiform Encephalopathies Advisory Committee||3014512392|
|Vaccines and Related Biological Products Advisory Committee||3014512391|
|CENTER FOR DRUG EVALUATION AND RESEARCH|
|Anesthetic and Life Support Drugs Advisory Committee||3014512529|
|Anti-Infective Drugs Advisory Committee||3014512530|
|Antiviral Drugs Advisory Committee||3014512531|
|Arthritis Advisory Committee||3014512532|
|Cardiovascular and Renal Drugs Advisory Committee||3014512533|
|Dermatologic and Ophthalmic Drugs Advisory Committee||3014512534|
|Drug Safety and Risk Management Advisory Committee||3014512535|
|Endocrinologic and Metabolic Drugs Advisory Committee||3014512536|
|Gastrointestinal Drugs Advisory Committee||3014512538|
|Nonprescription Drugs Advisory Committee||3014512541|
|Oncologic Drugs Advisory Committee||3014512542|
|Peripheral and Central Nervous System Drugs Advisory Committee||3014512543|
|Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly Advisory Committee for Pharmaceutical Science)||3014512539|
|Start Printed Page 9417|
|Psychopharmacologic Drugs Advisory Committee||3014512544|
|Pulmonary-Allergy Drugs Advisory Committee||3014512545|
|Reproductive Health Drugs, Advisory Committee for||3014512537|
|CENTER FOR FOOD SAFETY AND APPLIED NUTRITION|
|Food Advisory Committee||3014510564|
|CENTER FOR DEVICES AND RADIOLOGICAL HEALTH|
|Device Good Manufacturing Practice Advisory Committee||3014512398|
|Medical Devices Advisory Committee comprised of 18 panels)|
|Anesthesiology and Respiratory Therapy Devices Panel||3014512624|
|Circulatory System Devices Panel||3014512625|
|Clinical Chemistry and Clinical Toxicology Devices Panel||3014512514|
|Dental Products Panel||3014512518|
|Ear, Nose, and Throat Devices Panel||3014512522|
|Gastroenterology-Urology Devices Panel||3014512523|
|General and Plastic Surgery Devices Panel||3014512519|
|General Hospital and Personal Use Devices Panel||3014512520|
|Hematology and Pathology Devices Panel||3014512515|
|Immunology Devices Panel||3014512516|
|Medical Devices Dispute Resolution Panel||3014510232|
|Microbiology Devices Panel||3014512517|
|Molecular and Clinical Genetics Panel||3014510231|
|Neurological Devices Panel||3014512513|
|Ophthalmic Devices Panel||3014512396|
|Orthopaedic and Rehabilitation Devices Panel||3014512521|
|Radiological Devices Panel||3014512526|
|National Mammography Quality Assurance Advisory Committee||3014512397|
|Technical Electronic Product Radiation Safety Standards Committee||3014512399|
|CENTER FOR TOBACCO|
|Tobacco Products Scientific Advisory Committee||8732110002|
|CENTER FOR VETERINARY MEDICINE|
|Veterinary Medicine Advisory Committee||3014512548|
|NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)|
|Science Advisory Board to NCTR||3014512559|
The hotline will provide the most recent information available on upcoming advisory committee meetings, guidance for making an oral presentation during the open public hearing portion of a meeting, and procedures on obtaining copies of transcripts of advisory committee meetings. Because the hotline will communicate the most current information available about any particular advisory committee meeting, this system will provide interested parties with timely and equal access to such information. The hotline should Start Printed Page 9418also conserve agency resources by reducing the current volume of inquiries individual FDA offices and employees must handle concerning advisory committee schedules and procedures.
This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.Start Signature
Dated: February 24, 2010.
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-4258 Filed 3-1-10; 8:45 am]
BILLING CODE 4160-01-S